- Home
- ZYME vs NVRI Comparison
ZYME vs NVRI Comparison
Compare ZYME & NVRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZYME | NVRI |
|---|---|---|
| Founded | 2003 | 1853 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 996.0M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZYME | NVRI |
|---|---|---|
| Price | $26.58 | $18.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | 1.9M | ★ 2.6M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $134,481,000.00 | ★ $2,244,061,000.00 |
| Revenue This Year | $65.21 | N/A |
| Revenue Next Year | $20.39 | $3.72 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 116.21 | N/A |
| 52 Week Low | $9.03 | $4.72 |
| 52 Week High | $28.49 | $18.74 |
Technical Indicators
Market Signals| Indicator | ZYME | NVRI |
|---|---|---|
| Relative Strength Index (RSI) | 73.43 | 85.41 |
| Support Level | $21.89 | $12.87 |
| Resistance Level | $28.49 | $18.74 |
| Average True Range (ATR) | 1.53 | 0.74 |
| MACD | 0.65 | 0.58 |
| Stochastic Oscillator | 84.61 | 94.73 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.